Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
4.56M
-
Number of holders
-
266
-
Total shares
-
252M
-
Shares change
-
+43.9M
-
Total reported value, excl. options
-
$1.89B
-
Value change
-
+$323M
-
Put/Call ratio
-
2.48
-
Number of buys
-
175
-
Number of sells
-
-93
-
Price
-
$7.50
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) as of Q2 2024
filings reported holding RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q2 2024.
RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) has 266 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 252M shares
.
Largest 10 shareholders include ARK Investment Management LLC (28.1M shares), BAILLIE GIFFORD & CO (26.6M shares), VANGUARD GROUP INC (21.6M shares), BlackRock Inc. (17.3M shares), RA CAPITAL MANAGEMENT, L.P. (15.4M shares), Mubadala Investment Co PJSC (13M shares), Kinnevik AB (publ) (11.9M shares), Sumitomo Mitsui Trust Holdings, Inc. (9.99M shares), Nikko Asset Management Americas, Inc. (9.93M shares), and STATE STREET CORP (8.75M shares).
This table shows the top 266 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.